Table 3.
Antiviral activity (EC50-μM) on pre and post-infection treatment of ferruginol analogues 8 and 9.
| Compound | IC50 (μM) 72 h |
IC50 (μM) 8 days |
EC50 (μM) (SI) Pre-infection treatment |
EC50 (μM) (SI) Post-infection treatment |
||||
|---|---|---|---|---|---|---|---|---|
| HHV-1 | HHV-2 | DENV-2 | HHV-1 | HHV-2 | DENV-2 | |||
| 8 | 190.7 | 80.8 | NI | NI | NI | NI* | 19.2 (10.0) | 1.4 (57.7)* |
| 9 | 97.8 | 52.2 | NI | NI | NI | 19.6 (4.9) | 16.6 (5.9)* | 5.0 (10.4) |
| DEX-S | >10 | NT | 0.015 | 0.012 | NT | NT | NT | NT |
| ACV | >1700 | NT | NT | NT | NT | 2.2 | 0.27 | NT |
| RIBA | NT | NT | NT | NT | NT | NT | NT | 13.5 |
EC50, 50% antiviral effective concentration; IC50, 50% inhibitory concentration of cell proliferation (μM); SI, Antiviral selectivity index values (IC50/EC50) are presented between parenthesis; DEX-S, dextran sulfate; ACV, acyclovir; RIBA, ribavirin; *Reduction on viral plaque-size. NI, no inhibitory activity; NT, not tested. These values represent the mean of three independent experiments.